216 related articles for article (PubMed ID: 21654628)
21. B cells immortalized by a mini-Epstein-Barr virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells.
Moosmann A; Khan N; Cobbold M; Zentz C; Delecluse HJ; Hollweck G; Hislop AD; Blake NW; Croom-Carter D; Wollenberg B; Moss PA; Zeidler R; Rickinson AB; Hammerschmidt W
Blood; 2002 Sep; 100(5):1755-64. PubMed ID: 12176897
[TBL] [Abstract][Full Text] [Related]
22. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
[TBL] [Abstract][Full Text] [Related]
23. Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers.
Szmania S; Galloway A; Bruorton M; Musk P; Aubert G; Arthur A; Pyle H; Hensel N; Ta N; Lamb L; Dodi T; Madrigal A; Barrett J; Henslee-Downey J; van Rhee F
Blood; 2001 Aug; 98(3):505-12. PubMed ID: 11468143
[TBL] [Abstract][Full Text] [Related]
24. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
[TBL] [Abstract][Full Text] [Related]
25. Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy.
Sili U; Huls MH; Davis AR; Gottschalk S; Brenner MK; Heslop HE; Rooney CM
J Immunother; 2003; 26(3):241-56. PubMed ID: 12806278
[TBL] [Abstract][Full Text] [Related]
26. Epstein-Barr virus-transformed B-cells as efficient antigen presenting cells to propagate Aspergillus-specific cytotoxic T-lymphocytes.
Ramadan G
Egypt J Immunol; 2008; 15(1):145-57. PubMed ID: 20306679
[TBL] [Abstract][Full Text] [Related]
27. A single exercise bout enhances the manufacture of viral-specific T-cells from healthy donors: implications for allogeneic adoptive transfer immunotherapy.
Spielmann G; Bollard CM; Kunz H; Hanley PJ; Simpson RJ
Sci Rep; 2016 May; 6():25852. PubMed ID: 27181409
[TBL] [Abstract][Full Text] [Related]
28. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation.
Micklethwaite K; Hansen A; Foster A; Snape E; Antonenas V; Sartor M; Shaw P; Bradstock K; Gottlieb D
Biol Blood Marrow Transplant; 2007 Jun; 13(6):707-14. PubMed ID: 17531781
[TBL] [Abstract][Full Text] [Related]
29. Adenovirally transduced dendritic cells induce bispecific cytotoxic T lymphocyte responses against adenovirus and cytomegalovirus pp65 or against adenovirus and Epstein-Barr virus EBNA3C protein: a novel approach for immunotherapy.
Hamel Y; Blake N; Gabrielsson S; Haigh T; Jooss K; Martinache C; Caillat-Zucman S; Rickinson AB; Hacein-Bey S; Fischer A; Cavazzana-Calvo M
Hum Gene Ther; 2002 May; 13(7):855-66. PubMed ID: 11975851
[TBL] [Abstract][Full Text] [Related]
30. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.
Gottschalk S; Edwards OL; Sili U; Huls MH; Goltsova T; Davis AR; Heslop HE; Rooney CM
Blood; 2003 Mar; 101(5):1905-12. PubMed ID: 12411306
[TBL] [Abstract][Full Text] [Related]
31. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.
Bollard CM; Straathof KC; Huls MH; Leen A; Lacuesta K; Davis A; Gottschalk S; Brenner MK; Heslop HE; Rooney CM
J Immunother; 2004; 27(4):317-27. PubMed ID: 15235393
[TBL] [Abstract][Full Text] [Related]
32. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.
Tzannou I; Papadopoulou A; Naik S; Leung K; Martinez CA; Ramos CA; Carrum G; Sasa G; Lulla P; Watanabe A; Kuvalekar M; Gee AP; Wu MF; Liu H; Grilley BJ; Krance RA; Gottschalk S; Brenner MK; Rooney CM; Heslop HE; Leen AM; Omer B
J Clin Oncol; 2017 Nov; 35(31):3547-3557. PubMed ID: 28783452
[TBL] [Abstract][Full Text] [Related]
33. B lymphoblastoid cell lines as efficient APC to elicit CD8+ T cell responses against a cytomegalovirus antigen.
Sun Q; Burton RL; Dai LJ; Britt WJ; Lucas KG
J Immunol; 2000 Oct; 165(7):4105-11. PubMed ID: 11034422
[TBL] [Abstract][Full Text] [Related]
34. Stimulation by means of dendritic cells followed by Epstein-Barr virus-transformed B cells as antigen-presenting cells is more efficient than dendritic cells alone in inducing Aspergillus f16-specific cytotoxic T cell responses.
Zhu F; Ramadan G; Davies B; Margolis DA; Keever-Taylor CA
Clin Exp Immunol; 2008 Feb; 151(2):284-96. PubMed ID: 18005260
[TBL] [Abstract][Full Text] [Related]
35. Cytomegalovirus-specific cytotoxic T lymphocytes can be efficiently expanded from granulocyte colony-stimulating factor-mobilized hemopoietic progenitor cell products ex vivo and safely transferred to stem cell transplantation recipients to facilitate immune reconstitution.
Clancy LE; Blyth E; Simms RM; Micklethwaite KP; Ma CK; Burgess JS; Antonenas V; Shaw PJ; Gottlieb DJ
Biol Blood Marrow Transplant; 2013 May; 19(5):725-34. PubMed ID: 23380344
[TBL] [Abstract][Full Text] [Related]
36. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.
Liu Z; Savoldo B; Huls H; Lopez T; Gee A; Wilson J; Brenner MK; Heslop HE; Rooney CM
Recent Results Cancer Res; 2002; 159():123-33. PubMed ID: 11785836
[TBL] [Abstract][Full Text] [Related]
37. Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells.
Subklewe M; Sebelin K; Block A; Meier A; Roukens A; Paludan C; Fonteneau JF; Steinman RM; Münz C
Hum Immunol; 2005 Sep; 66(9):938-49. PubMed ID: 16360833
[TBL] [Abstract][Full Text] [Related]
38. Characterization of a Cytomegalovirus-Specific T Lymphocyte Product Obtained Through a Rapid and Scalable Production Process for Use in Adoptive Immunotherapy.
Grau-Vorster M; López-Montañés M; Cantó E; Vives J; Oliver-Vila I; Barba P; Querol S; Rudilla F
Front Immunol; 2020; 11():271. PubMed ID: 32161589
[TBL] [Abstract][Full Text] [Related]
39. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.
Hanley PJ; Cruz CR; Savoldo B; Leen AM; Stanojevic M; Khalil M; Decker W; Molldrem JJ; Liu H; Gee AP; Rooney CM; Heslop HE; Dotti G; Brenner MK; Shpall EJ; Bollard CM
Blood; 2009 Aug; 114(9):1958-67. PubMed ID: 19443656
[TBL] [Abstract][Full Text] [Related]
40. Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells.
Tischer S; Priesner C; Heuft HG; Goudeva L; Mende W; Barthold M; Kloeß S; Arseniev L; Aleksandrova K; Maecker-Kolhoff B; Blasczyk R; Koehl U; Eiz-Vesper B
J Transl Med; 2014 Dec; 12():336. PubMed ID: 25510656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
